Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The selection of a next generation Immunoglobulin A (IgA) protease from IGAN Biosciences for its IgA nephropathy (IgAN) program, will lead Selecta Biosciences to pay IGAN Biosciences.
Lead Product(s): Undisclosed
Therapeutic Area: Nephrology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Selecta Biosciences
Deal Size: $1.6 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 14, 2022
Details:
The companies have entered into a Research License and Option agreement to study Selecta’s ImmTOR™ immune tolerance platform in combination with IGAN’s immunoglobulin A (IgA) protease for the treatment of IgA Nephropathy (IgAN).
Lead Product(s): Pegadricase,IgA proteases
Therapeutic Area: Immunology Product Name: SEL-212
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Selecta Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 08, 2020